TY - JOUR AU - Szakály, Zsolt Károly AU - Pápai, Zsófia AU - Liszkai, Zsuzsanna AU - Dézsiné, Szentes Veronika AU - Dézsi, Csaba András TI - A testvíztartalom változása a tápláltsági állapot és az életkor függvényében JF - ORVOSI HETILAP J2 - ORV HETIL VL - 165 PY - 2024 IS - 43 SP - 1694 EP - 1699 PG - 6 SN - 0030-6002 DO - 10.1556/650.2024.33149 UR - https://m2.mtmt.hu/api/publication/35483206 ID - 35483206 N1 - Széchenyi István Egyetem, Egészség- és Sporttudományi Kar, Sporttudományi Tanszék, Gyor, Hungary Széchenyi István Egyetem, Apáczai Csere János Pedagógiai, Humánés Társadalomtudományi Kar, Szakmódszertani Tanszék, Gyor, Hungary Széchenyi István Egyetem, Egészségés Sporttudományi Kar, Egészségés Ápolástudományi Tanszék, Szent Imre út 25-27., 9026, Hungary Petz Aladár Egyetemi Oktató Kórház, Kardiológiai Osztály, Gyor, Hungary Export Date: 09 January 2025; Cited By: 0; CODEN: ORHEA LA - Hungarian DB - MTMT ER - TY - JOUR AU - Dézsi, Csaba András AU - Andréka, Judit AU - Sayour, Amer M. AU - Deák, Mónika AU - Szentes, Veronika AU - Sebők, Zoltán AU - Fi, Zsolt AU - Achim, Alexandru AU - Ruzsa, Zoltán TI - Long-term clinical and angiographic outcome of T-and protrusion technique with ultrathin strut drug eluting stents JF - FUTURE CARDIOLOGY J2 - FUTURE CARDIOL VL - 20 PY - 2024 IS - 15-16 SP - 837 EP - 842 PG - 6 SN - 1479-6678 DO - 10.1080/14796678.2024.2435205 UR - https://m2.mtmt.hu/api/publication/35627714 ID - 35627714 N1 - Faculty of Health and Sports Sciences, Department of Health, and Nursing Sciences, Széchenyi István University, Győr, Hungary Department of Cardiology, Győr-Moson-Sopron County Petz A. University Teaching Hospital, Győr, Hungary Internal Medicine Department, Division of Invasive Cardiology, University of Szeged, Szeged, Hungary Department of Cardiology, University Heart Center Graz, Graz, Austria Export Date: 09 January 2025; Cited By: 0; Correspondence Address: Z. Ruzsa; CONTACT Zoltán Ruzsa, Faculty of Medicine, Internal Medicine Department, Invasive Cardiology Division, University of Szeged, Szeged, Semmelweis Str 8, 6726, Hungary; email: ruzsa.zoltan@med.u-szeged.hu LA - English DB - MTMT ER - TY - JOUR AU - Szili, K AU - Bozsár, S AU - Lábodi, L AU - Cserháti, N AU - Friedl, M AU - Szabóné, Ábrahám Z AU - Dézsi, Csaba András TI - ALAPELLÁTÁSI PILOT A NÉPBETEGSÉGEK KORAI FELISMERÉSÉRE ÉS HOLISZTIKUS KEZELÉSÉRE JF - MAGYAR BELORVOSI ARCHIVUM J2 - MBA VL - 77 PY - 2024 IS - 5-6 SP - 358 EP - 358 PG - 1 SN - 0133-5464 UR - https://m2.mtmt.hu/api/publication/35717488 ID - 35717488 LA - Hungarian DB - MTMT ER - TY - JOUR AU - Szakály, Zsolt Károly AU - Pápai, Zsófia AU - Liszkai, Zsuzsanna AU - Bognár, József AU - Dézsi, Csaba András TI - Férfi fizikai dolgozók testösszetételének jellemzői: középpontban az életkor JF - ORVOSI HETILAP J2 - ORV HETIL VL - 164 PY - 2023 IS - 3 SP - 96 EP - 103 PG - 8 SN - 0030-6002 DO - 10.1556/650.2023.32662 UR - https://m2.mtmt.hu/api/publication/33582860 ID - 33582860 N1 - Export Date: 18 February 2024 CODEN: ORHEA Correspondence Address: András, D.C.; Széchenyi István Egyetem, Szent Imre út 25-27, Hungary; email: dcsa62@gmail.com Tradenames: Inbody 720 LA - Hungarian DB - MTMT ER - TY - JOUR AU - Papp, Tímea Bianka AU - Kiss, Zoltán AU - Rokszin, György Aurél AU - Bajcsayné Fábián, Ibolya AU - Márk, László AU - Bagoly, Zsuzsa AU - Becker, Dávid AU - Merkely, Béla Péter AU - Aradi, Dániel AU - Dézsi, Csaba András AU - Járai, Zoltán AU - Csanádi, Zoltán TI - Mortality on DOACs Versus on Vitamin K Antagonists in Atrial Fibrillation: Analysis of the Hungarian Health Insurance Fund Database JF - CLINICAL THERAPEUTICS J2 - CLIN THER VL - 45 PY - 2023 IS - 4 SP - 333 EP - 346 PG - 14 SN - 0149-2918 DO - 10.1016/j.clinthera.2023.03.008 UR - https://m2.mtmt.hu/api/publication/33742453 ID - 33742453 AB - Limited real-world data are available on the survival of patients treated with vitamin K antagonists (VKAs) versus with direct oral anticoagulants (DOACs) for nonvalvular atrial fibrillation (AF). In this nationwide registry, we analyzed the mortality risk of patients with nonvalvular AF taking DOACs versus VKAs, with a special attention to the early treatment period.The Hungarian National Health Insurance Fund (NHIF) database was searched to identify patients treated with VKA or DOAC as a thromboembolic prophylaxis for nonvalvular AF between 2011 and 2016. The overall and the early (0-3, 4-6, and 7-12 months) mortality risks with the 2 types of anticoagulation were compared. A total of 144,394 patients with AF treated with either a VKA (n = 129,925) or a DOAC (n = 14,469) were enrolled.A 28% improvement in 3-year survival with DOAC treatment compared with VKA treatment was shown. Mortality reduction with DOACs was consistent across different subgroups. However, younger patients (30-59 years old) initiated on DOAC therapy had the greatest RRR (53%) in mortality. Furthermore, DOAC treatment also yielded a benefit of greater magnitude (HR = 0.55; 95% CI, 0.40-0.77, P = 0.001) in the lower (0-1) CHA2DS2-VASc score segment and in those with fewer (0-1) bleeding risk factors (HR = 0.50, CI 0.34-0.73, P = 0.001). The RRR in mortality with DOACs was 33% within the first 3 months, and 6% in the second year.Thromboembolic prophylaxis with DOACs in this study yielded significantly lower mortality compared with VKA treatment in patients with nonvalvular AF. The largest benefit was shown in the early period after treatment initiation, as well as in younger patients, those with a lower CHA2DS2-VASc score, and those with fewer bleeding risk factors. LA - English DB - MTMT ER - TY - JOUR AU - Tar, Balázs AU - Jenei, Csaba AU - Üveges, Áron AU - Szabó, Gábor Tamás AU - Ágoston, András AU - Dézsi, Csaba András AU - Komócsi, András AU - Czuriga, Dániel AU - Juhász, Attila AU - Kőszegi, Zsolt TI - Hyperemic contrast velocity assessment improves accuracy of the image-based fractional flow reserve calculation JF - CARDIOLOGY JOURNAL J2 - CARDIOL J VL - 28 PY - 2021 IS - 1 SP - 163 EP - 165 PG - 3 SN - 1897-5593 DO - 10.5603/CJ.a2020.0144 UR - https://m2.mtmt.hu/api/publication/31627991 ID - 31627991 N1 - Terjedelme meghaladja a 10.000 karaktert, így az V.o. ajánlása alapján rövid közlemény. LA - English DB - MTMT ER - TY - JOUR AU - Dézsi, Csaba András AU - Glezer, Maria AU - Karpov, Yuri AU - Brzozowska-Villatte, Romualda AU - Farsang, Csaba TI - Effectiveness of Perindopril/Indapamide Single-Pill Combination in Uncontrolled Patients with Hypertension: A Pooled Analysis of the FORTISSIMO, FORSAGE, ACES and PICASSO Observational Studies JF - ADVANCES IN THERAPY J2 - ADV THER VL - 38 PY - 2021 IS - 1 SP - 479 EP - 494 PG - 16 SN - 0741-238X DO - 10.1007/s12325-020-01527-3 UR - https://m2.mtmt.hu/api/publication/31671935 ID - 31671935 N1 - Funding Agency and Grant Number: Servier, FranceServier; Servier, Russia; Egis Pharmaceutical Ltd., Hungary; Servier (I.R.I.S.), France Servier AB - Introduction Our objective was to determine the effectiveness of a perindopril/indapamide (Per/Ind) single-pill combination (SPC) in a broad range of patient profiles, including subgroups with varying hypertension severity, age and cardiovascular risk profiles. Methods Patient data from four large prospective observational studies (FORTISSIMO, FORSAGE, PICASSO, ACES) were pooled. In each study, patients already treated for hypertension were switched to Per/Ind 10/2.5 mg SPC and systolic and diastolic blood pressure (SBP/DBP) measured at the 1-month (M1) and 3-month (M3) visits. Study endpoints included change in SBP and DBP from baseline to M1 and M3 and the percentage of patients achieving BP control (SBP/DBP < 140/90 mmHg for patients without diabetes or < 140/85 mmHg for patients with diabetes). Results A total of 16,763 patients were enrolled and received Per/Ind (94% received the full dose of 10/2.5). Mean patient age was 61.4 years (36% were >= 65 years old), 57% were women, and 16% had isolated systolic hypertension (ISH). Mean baseline office SBP/DBP was 162/94 mmHg, and mean duration of hypertension was 11 years. Cardiovascular risk factors and comorbid conditions were common in this population. Significant mean reductions in SBP (- 23 mmHg) and DBP (- 11 mmHg) were observed at M1 compared with baseline (P < 0.001), which were maintained at M3 (- 30 mmHg and - 14 mmHg, respectively). At M3, BP control was achieved by 70% of patients (78% for ISH). In patients with SBP >= 180 mmHg at baseline (grade III hypertension), the mean SBP/DBP decrease was - 51/- 20 mmHg and 53% achieved BP control. Per/Ind was well tolerated with an overall rate of adverse events of 1.3%, most frequently cough and dizziness at rates of 0.3% and 0.2%, respectively. Conclusion In this hypertensive population including difficult-to-control patient subgroups, switching to Per/Ind 10/2.5 mg SPC led to rapid and important reductions in BP. BP control was achieved in 70% of patients overall in an everyday practice context. LA - English DB - MTMT ER - TY - JOUR AU - Kiss, Zoltan AU - Márk, László AU - Herczeg, Béla AU - Aradi, Dániel AU - Rokszin, György Aurél AU - Bajcsayné Fábián, Ibolya AU - Horváth, Krisztián AU - Wittmann, István AU - Kiss, Róbert AU - Dézsi, Csaba András AU - Csanádi, Zoltán AU - Merkely, Béla TI - Improvement in age- and sex-dependent mortality in patients with atrial fibrillation between 2011 and 2016 – a nationwide retrospective study from Hungary JF - ARCHIVES OF MEDICAL SCIENCE J2 - ARCH MED SCI VL - 2021 PY - 2021 SN - 1734-1922 DO - 10.5114/aoms/128390 UR - https://m2.mtmt.hu/api/publication/31820559 ID - 31820559 LA - English DB - MTMT ER - TY - JOUR AU - Farsang, Csaba AU - Dézsi, Csaba András AU - Brzozowska-Villatte, Romualda AU - De, Champvallins Martine AU - Glezer, Maria AU - Karpov, Yuri TI - Beneficial Effects of a Perindopril/Indapamide Single-Pill Combination in Hypertensive Patients with Diabetes and/or Obesity or Metabolic Syndrome: A Post Hoc Pooled Analysis of Four Observational Studies JF - ADVANCES IN THERAPY J2 - ADV THER VL - 38 PY - 2021 IS - 4 SP - 1776 EP - 1790 PG - 15 SN - 0741-238X DO - 10.1007/s12325-021-01619-8 UR - https://m2.mtmt.hu/api/publication/31930771 ID - 31930771 N1 - Cited By :3 Export Date: 19 October 2022 CODEN: ADTHE Correspondence Address: Farsang, C.; Semmelweis University Pharmacology and Therapeutics and St. Imre University Teaching HospitalHungary; email: hunghyp@t-online.hu Chemicals/CAS: cholesterol, 57-88-5; creatinine, 19230-81-0, 60-27-5; glucose, 50-99-7, 84778-64-3; indapamide, 26807-65-8; perindopril, 82834-16-0, 99149-83-4; potassium, 7440-09-7; sodium, 7440-23-5; uric acid, 69-93-2; Antihypertensive Agents; Drug Combinations; Indapamide; Perindopril AB - Introduction To assess real-life effectiveness of a perindopril/indapamide (Per/Ind) single-pill combination (SPC) in patients with hypertension (HT) and type 2 diabetes mellitus (T2DM), obesity and/or metabolic syndrome (MetS). Methods This post hoc analysis pooled raw data from four large observational studies (FORTISSIMO, FORSAGE, ACES, PICASSO). Patients, most with uncontrolled blood pressure (BP) on previous treatments were switched to Per/Ind (10 mg/2.5 mg) SPC at study entry. Office systolic and diastolic blood pressures (SBP and DBP) were measured at baseline, 1 month and 3 months. Results In the overall pooled population (N = 16,763), mean age was 61 +/- 12 years, HT duration 11 +/- 8 years, and baseline SBP/DBP 162/94 mmHg. T2DM, obesity and MetS were present in 21%, 49% and 27% of patients, respectively. Subgroups had similar mean age and HT duration to the overall population; patients with T2DM were slightly older (64 +/- 10 years) with a longer HT duration (13 +/- 8 years). Mean BP was approximately 160/95 mmHg in each subgroup. At 1 month, mean SBP decreased by approximately 20 mmHg in the overall population, and by a further 10 mmHg at 3 months. Similar results were observed in the three subgroups, with mean changes from baseline at 3 months of - 28 +/- 15/- 13 +/- 10 in T2DM; - 30 +/- 15/- 14 +/- 10 in obesity; and - 31 +/- 15/- 15 +/- 9 mmHg in MetS. BP decreases were greatest in patients with grade II or grade III HT. BP control rates (< 140/90 mmHg or 140/85 mmHg for T2DM) at 3 months were 59% in T2DM, 67% in obese, and 66% in MetS. No specific safety concerns were raised, particularly concerning ionic (Na, K) or metabolic profiles. Conclusions Switching to Per/Ind SPC led to rapid and effective BP decreases in patients with T2DM, obesity, or MetS. BP control was achieved in 6-7 out of 10 previously treated but uncontrolled patients. Treatment was well tolerated. The results confirm the beneficial effects of a Per/Ind SPC for difficult-to-control patient populations. LA - English DB - MTMT ER - TY - JOUR AU - Dézsi, Csaba András TI - Hogyan kezeljük a hipertóniás betegeinket 2021-ben? JF - METABOLIZMUS J2 - METABOLIZMUS VL - 19 PY - 2021 IS - 2 SP - 108 EP - 111 PG - 4 SN - 1589-7311 UR - https://m2.mtmt.hu/api/publication/32052347 ID - 32052347 LA - Hungarian DB - MTMT ER -